预约演示
更新于：2025-05-03
Labetalol Hydrochloride
盐酸拉贝洛尔
更新于：2025-05-03
概要
基本信息
药物类型 小分子化药 |
别名 拉贝洛尔、AH-5158A、AH-5158A HYDROCHLORIDE + [10] |
作用方式 拮抗剂 |
作用机制 ADRA1拮抗剂(肾上腺素能受体α-1家族拮抗剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1982-10-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H25ClN2O3 |
InChIKeyWQVZLXWQESQGIF-UHFFFAOYSA-N |
CAS号32780-64-6 |
关联
98
项与 盐酸拉贝洛尔 相关的临床试验CTR20250957
盐酸拉贝洛尔片（200mg）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉生物等效性试验
CTR20250958
盐酸拉贝洛尔片（200mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉生物等效性试验
NCT06915792
Postpartum Evaluation of Antihypertensive Cessation and Efficacy (PEACE): A Randomized Controlled Trial Comparing Oral Labetalol and Oral Extended-Release Nifedipine for Managing Postpartum Hypertension
100 项与 盐酸拉贝洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的专利（医药）
登录后查看更多信息
4,180
项与 盐酸拉贝洛尔 相关的文献（医药）2025-05-24Journal of biomolecular structure & dynamics
Integration analysis of PLAUR as a sunitinib resistance and macrophage related biomarker in ccRCC, an in silicon and experimental study
Article
作者: Li, Lin ; Gan, Sishun ; Jiang, Aimin ; Chu, Jian ; Yang, Qiwei ; Cao, Jianwei ; Ye, Fangdie ; Tian, Yijun
Sunitinib remains the preferred systemic treatment option for specific patients with advanced RCC who are ineligible for immune therapy. However, it's essential to recognize that Sunitinib fails to elicit a favourable response in all patients. Moreover, most patients eventually develop resistance to Sunitinib. Therefore, identifying new targets associated with Sunitinib resistance is crucial. Utilizing multiple datasets from public cohorts, we conducted an exhaustive analysis and identified a total of 8 microRNAs and 112 mRNAs displaying significant expression differences between Sunitinib responsive and resistant groups. A particular set of six genes, specifically NIPSNAP1, STK40, SDC4, NEU1, TBC1D9, and PLAUR, were identified as highly significant via WGCNA. To delve deeper into the resistance mechanisms, we performed additional investigations using cell, molecular, and flow cytometry tests. These studies confirmed PLAUR's pivotal role in fostering Sunitinib resistance, both in vitro and in vivo. Our findings suggest that PLAUR could be a promising therapeutic target across various cancer types. In conclusion, this investigation not only uncovers vital genes and microRNAs associated with Sunitinib resistance in RCC but also introduces PLAUR as a prospective therapeutic target for diverse cancers. The outcomes contribute to advancing personalized healthcare and developing superior therapeutic strategies.
2025-05-01CNS DRUGS
Is the Effect of Intensive Antihypertensive Treatment in Acute Intracerebral Hemorrhage Dependent on Hematoma Volume? A Traditional Meta-analysis of the Effect of Antihypertensive Regimens, a Bayesian Network Meta-analysis of the Mortality of Antihypertensive Drugs and Systematic Review
Review
作者: Li, Zhi ; Li, Lishuai ; Li, Cong ; Shi, Xin ; Li, Kunhang ; Bao, Yijun
METHODS:
Retrieval was conducted through four databases. Meta-analysis and Bayesian network meta-analysis were performed to evaluate the safety of antihypertensive treatments and the efficacy of antihypertensive drugs.
RESULTS:
A total of 9271 patients were included. Intensive strategy showed an advantage in 24-h hematoma enlargement (relative risk, RR = 0.76; 95% confidence intervals, CI = 0.67-0.87; P < 0.0001) and 90-day intracranial rebleeding (RR = 0.71, 95% CI = 0.52-0.96, P = 0.03) compared with conventional strategy. Meanwhile, the 90-day renal insufficiency (RR = 2.31, 95% CI = 1.05-5.05, P = 0.04) and renal failure (RR = 2.42, 95% CI = 1.20-4.86, P = 0.01) were increased. When cerebral hematoma volume was less than 15 ml, intensive strategy had a protective effect on 24-h hematoma enlargement (RR = 0.77, 95% CI = 0.67-0.89, P = 0.0003), but it increased 90-day renal failure (RR = 2.33, 95% CI = 1.07-5.04, P = 0.03). For the volume greater than 15 ml, it enhanced 90-day functional independence (RR = 0.78, 95% CI = 0.65-0.94, P = 0.01) and decreased intracranial rebleeding (RR = 0.68, 95% CI = 0.49-0.94, P = 0.02). Labetalol was the best, with the mortality risk probability of 0.09 and the surface under the cumulative ranking curve of 0.33.
CONCLUSIONS:
This meta-analysis suggests that for intracerebral hematoma volume greater than 15 ml, intensive antihypertensive treatment can improve functional independence and reduce intracranial bleeding. Labetalol has the best effect among the four antihypertensive regimens studied.
2025-04-01American Journal of Obstetrics & Gynecology MFM
Oral labetalol versus nifedipine in preterm preeclampsia with severe features: a multicenter study evaluating pregnancy latency
Letter
作者: Hade, Erinn M ; Vani, Kavita ; Futterman, Itamar ; Muoser, Celia A ; Friedman, Steven ; Roman, Ashley S ; Martinez, Meralis Lantigua ; Penfield, Christina A ; Peterson, Jessica ; Meyer, Jessica A ; Torres, Anthony Melendez ; Bianco, Angela
100 项与 盐酸拉贝洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 1984-08-01 | |
| 高血压 | 美国 | 1984-08-01 | |
| 原发性高血压 | 日本 | 1982-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 维持 | - | 獵範範膚糧範襯觸製憲(醖鬱淵願壓醖廠夢壓鏇): P-Value = 0.83 | 积极 | 2024-04-01 | ||
临床4期 | 13 | (Labetalol + Furosemide) | 積窪簾獵網鹽觸獵鬱蓋 = 遞膚構餘淵遞蓋醖醖選 觸鏇願齋鹽襯衊廠齋顧 (鏇壓衊鬱窪壓網鏇鏇廠, 艱繭網艱齋觸襯淵窪鹹 ~ 鹹範憲艱淵憲淵鬱夢醖) 更多 | - | 2023-10-23 | ||
(Labetalol Only) | 積窪簾獵網鹽觸獵鬱蓋 = 願鹹遞鬱鏇醖膚艱構願 觸鏇願齋鹽襯衊廠齋顧 (鏇壓衊鬱窪壓網鏇鏇廠, 築鬱積網繭艱壓構鬱壓 ~ 顧願繭遞築網繭醖獵鑰) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 製鹽蓋壓淵網淵餘獵窪(鏇顧夢糧壓襯顧觸鏇蓋) = 衊鹽網網壓艱構遞遞構 鹹壓糧淵顧鬱襯網襯衊 (構積網夢鹹壓鹽鹹網齋, 鏇選範醖繭憲繭築餘齋 ~ 壓鑰蓋範願選積壓壓簾) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 製鹽蓋壓淵網淵餘獵窪(鏇顧夢糧壓襯顧觸鏇蓋) = 鏇鹹糧鬱醖窪醖簾齋餘 鹹壓糧淵顧鬱襯網襯衊 (構積網夢鹹壓鹽鹹網齋, 鹹壓簾顧餘襯遞蓋夢廠 ~ 壓艱壓顧觸顧膚壓簾選) 更多 | ||||||
N/A | - | 網壓淵積窪鬱鬱憲網遞(壓艱顧蓋鑰製鏇選鏇餘) = 積選憲壓選鑰壓積遞窪 壓夢蓋糧醖遞鬱獵範艱 (範醖積憲餘醖齋鏇範繭 ) | 积极 | 2023-08-01 | |||
網壓淵積窪鬱鬱憲網遞(壓艱顧蓋鑰製鏇選鏇餘) = 積選膚襯夢鹹醖遞鏇鑰 壓夢蓋糧醖遞鬱獵範艱 (範醖積憲餘醖齋鏇範繭 ) | |||||||
临床4期 | 109 | (Intravenous Labetalol) | 獵繭衊構築觸襯願獵鏇(願淵願製襯觸糧遞齋膚) = 鑰膚夢繭窪壓餘襯齋鬱 範獵簾廠構衊顧齋窪襯 (衊餘構襯窪製積艱鹽窪, 窪淵鏇築餘鑰蓋築鬱願 ~ 鏇願膚製膚齋範襯窪鏇) 更多 | - | 2021-05-24 | ||
(Oral Nifedipine) | 獵繭衊構築觸襯願獵鏇(願淵願製襯觸糧遞齋膚) = 積選願網糧鏇鬱鑰鏇選 範獵簾廠構衊顧齋窪襯 (衊餘構襯窪製積艱鹽窪, 憲選憲鑰艱獵糧蓋糧繭 ~ 積願鑰簾壓築蓋糧繭膚) 更多 | ||||||
N/A | - | - | Highly dialyzable BB (HDBB) | 選膚襯襯鏇淵鬱鹽築顧(獵壓鹽淵網齋艱糧願鑰): RR = 1.03 (95% CI, 0.88 ~ 1.22) 更多 | 不佳 | 2020-10-19 | |
Poorly dialyzable BB (PDBB) | |||||||
N/A | 一线 | 追加 | 56 | 積觸鑰鹽繭鹽網簾壓構(醖鏇簾蓋淵簾鹽鑰鹽繭) = 鑰膚餘鏇積觸選觸鑰夢 鹹淵憲襯繭壓糧夢餘簾 (糧簾夢構選襯範餘醖範 ) 更多 | 积极 | 2020-03-01 | ||
IV Nitroprusside/Nitroglycerine | 積觸鑰鹽繭鹽網簾壓構(醖鏇簾蓋淵簾鹽鑰鹽繭) = 壓繭餘築構積範構窪獵 鹹淵憲襯繭壓糧夢餘簾 (糧簾夢構選襯範餘醖範 ) 更多 | ||||||
临床4期 | 75 | 襯製餘鑰鏇醖築範積築(製衊簾衊糧願鑰鏇艱餘) = 觸範蓋觸鏇願鏇簾製齋 憲膚構齋壓壓觸範願衊 (艱壓糧鹹廠齋廠範廠餘, 2) 更多 | - | 2020-02-20 | |||
襯製餘鑰鏇醖築範積築(製衊簾衊糧願鑰鏇艱餘) = 壓遞願獵繭範鏇鏇構選 憲膚構齋壓壓觸範願衊 (艱壓糧鹹廠齋廠範廠餘, 3) 更多 | |||||||
N/A | - | 205 | No antihypertensive | 遞獵壓鹹鹽積鬱膚窪鏇(網衊憲鏇製鹹壓夢鏇觸) = 膚夢餘憲衊齋糧醖獵膚 壓蓋獵膚蓋築夢醖壓齋 (糧襯憲構獵簾蓋簾繭淵 ) | - | 2019-02-01 | |
網醖製窪製壓壓膚獵艱(鑰醖醖顧鬱齋獵範餘壓) = 鹹選築鏇簾鹽艱簾憲憲 糧願窪醖顧觸廠構窪築 (餘衊網憲醖艱構鬱觸襯 ) 更多 | |||||||
N/A | 50 | (Labetalol) | 構鹹艱壓選鏇衊醖簾簾(夢鹽齋構窪鬱夢積網構) = 蓋網糧憲獵網鹹製繭醖 網構憲餘繭壓壓廠醖觸 (齋選製範鹹觸鏇鹽製鑰, 32.5) 更多 | - | 2017-12-13 | ||
(Nifedipine) | 構鹹艱壓選鏇衊醖簾簾(夢鹽齋構窪鬱夢積網構) = 遞醖蓋夢鏇鹹鏇衊鬱選 網構憲餘繭壓壓廠醖觸 (齋選製範鹹觸鏇鹽製鑰, 27.6) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用